Cargando…

P999: ROLE OF GENETIC VARIANTS IN PREDICTING EFFICACY AND/OR ADVERSE EVENTS OF ROPEGINTERFERON ALPHA-2B IN MPN PATIENTS: A RETROSPECTIVE ANALYSIS FROM AN ASIAN COHORT

Detalles Bibliográficos
Autores principales:	Chen, Chih-Cheng, Kuo, Ming-Chung, Wang, Ying-Hsuan, Pei, Sung-Nan, Huang, Ming-Lih, Chen, Chiu-Chen, Huang, Cih-En, Chen, Yi-Yang, Shih, Lee-Yung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431422/ http://dx.doi.org/10.1097/01.HS9.0000970900.52841.48

Ejemplares similares

Mutation-Driven S100A8 Overexpression Confers Aberrant Phenotypes in Type 1 CALR-Mutated MPN
por: Wang, Ying-Hsuan, et al.
Publicado: (2023)

P984: DIFFERENTIAL IMPACTS OF DISTINCT MUTATION SUBTYPES ON ALTERED S100A8 EXPRESSION AND PHENOTYPIC HETEROGENEITY IN CALR-MUTANT MPN
por: Chen, Ying-Ju, et al.
Publicado: (2023)

999 : el último guardián /
por: Martigli, Carlo A.
Publicado: (2010)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
por: Lin, Hsien‐Hong, et al.
Publicado: (2021)

Posters P788 - P999
Publicado: (2005)

Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan
por: Chen, Kuan-Yuan, et al.
Publicado: (2021)

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
por: Gisslinger, Heinz, et al.
Publicado: (2020)

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
por: Verger, Emmanuelle, et al.
Publicado: (2018)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
por: Gerds, Aaron T, et al.
Publicado: (2023)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2022)

A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse
por: Srivastava, Barnali, et al.
Publicado: (2023)

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
por: Kaifie, A., et al.
Publicado: (2016)

999 The Role of Quantitative Blood PCR in the Management of Congenital Cytomegalovirus Infection
por: Leduc, Dorothée, et al.
Publicado: (2014)

Immunomodulatory and direct activities of ropeginterferon alfa‐2b on cancer cells in mouse models of leukemia
por: Sakatoku, Kazuki, et al.
Publicado: (2022)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients
por: Palmer, Jeanne M., et al.
Publicado: (2020)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
por: Okikiolu, Jumoke, et al.
Publicado: (2022)

The Icelandic founder mutation BRCA2 999del5: analysis of expression
por: Mikaelsdottir, Evgenia K, et al.
Publicado: (2004)

Prehospital recognition and antibiotics for 999 patients with sepsis: protocol for a feasibility study
por: Moore, Chris, et al.
Publicado: (2018)

Correction to: Toothpaste and mouthwash inactivate 99.9% of the virus that causes COVID-19
Publicado: (2021)

999. Nasal Mucosal Cytokines: Potential Biomarkers for Pediatric Pneumonia Severity and Etiology
por: Sayegh, Rouba, et al.
Publicado: (2021)

Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects
por: Zhu, Min, et al.
Publicado: (2021)

Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2020)

Renal biopsy cases in myeloproliferative neoplasms (MPN)
por: Fujita, Kumi, et al.
Publicado: (2013)

A knockout combination for MPN stem cells
por: Bywater, Megan, et al.
Publicado: (2020)

Chronic myeloid leukemia: a type of MPN
por: Samad, Muhammad Ammar, et al.
Publicado: (2022)

Breakthrough infections in MPN-COVID vaccinated patients
por: Barbui, Tiziano, et al.
Publicado: (2022)

The Story of the Dopamine Transporter PET Tracer LBT-999: From Conception to Clinical Use
por: Chalon, Sylvie, et al.
Publicado: (2019)

S211: EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS
por: Gill, Harry, et al.
Publicado: (2023)

Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
por: Kricheldorf, Kim, et al.
Publicado: (2021)

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
por: Schmidt, Andreas, et al.
Publicado: (2023)

The Impact of Influenza Vaccinations on the Adverse Effects and Hospitalization Rate in the Elderly: A National Based Study in an Asian Country
por: Ho, Tsung-Yu, et al.
Publicado: (2012)

Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN
por: Stegelmann, Frank, et al.
Publicado: (2021)

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
por: Gisslinger, Heinz, et al.
Publicado: (2023)

The Hen or the Egg: Inflammatory Aspects of Murine MPN Models
por: Jutzi, Jonas S., et al.
Publicado: (2015)

Impact of Host, Lifestyle and Environmental Factors in the Pathogenesis of MPN
por: Ramanathan, Gajalakshmi, et al.
Publicado: (2020)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
por: Baumeister, Julian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s6qbhu7f40ql5afrb91lrgnvnc